Tetratherix LimitedASX: TTX

CEO Address to Shareholders

· Issued by Tetratherix Limited via ASX

Filed with ASX · · 2 pages · English

Summary by 6ix AI

The CEO discusses the company's progress in developing its Tetramatrix innovation and achieving revenue generation for the first time. Key highlights include FDA submissions for bone regeneration products and partnerships with major companies in the medical field.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX Release ASX:TTX CEO REMARKS 2026 AGM 12 November 2026 In accordance with Listing Rule 3.13.3, please see the remarks to be presented at the Tetratherix Limited (ASX:TTX) (Tetratherix) 2026 AGM by Will Knox our CEO. A year ago we listed on the ASX with a clear thesis and FY26 was the year we put...

Tetratherix Limited on 6ix

Earlier from Tetratherix

Later from Tetratherix

All Tetratherix news releases